Novartis: Beovu shows signs of improving visual acuity
(CercleFinance.com) - Novartis said the results of two Phase III studies of wet AMD patients showed that Beovu improved visual acuity.
The Swiss drugmaker said new post-hoc analyses demonstrated fewer Beovu patients had early persistent fluid, defined as the presence of intra-retinal fluid and/or sub-retinal fluid through week 12 of treatment, compared with aflibercept patients.
An analysis in particular showed Beovu was associated with better control of retinal fluid, as measured by achievement and maintenance of central subfield thickness (CST) levels, it said.
In the study, more Beovu patients than aflibercept patients achieved CST control (80% compared to 69%), Novartis said.
The data have been presented at the EURETINA 2020 virtual congress.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Swiss drugmaker said new post-hoc analyses demonstrated fewer Beovu patients had early persistent fluid, defined as the presence of intra-retinal fluid and/or sub-retinal fluid through week 12 of treatment, compared with aflibercept patients.
An analysis in particular showed Beovu was associated with better control of retinal fluid, as measured by achievement and maintenance of central subfield thickness (CST) levels, it said.
In the study, more Beovu patients than aflibercept patients achieved CST control (80% compared to 69%), Novartis said.
The data have been presented at the EURETINA 2020 virtual congress.
Copyright (c) 2020 CercleFinance.com. All rights reserved.